SG11201808106YA - Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation - Google Patents
Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulationInfo
- Publication number
- SG11201808106YA SG11201808106YA SG11201808106YA SG11201808106YA SG11201808106YA SG 11201808106Y A SG11201808106Y A SG 11201808106YA SG 11201808106Y A SG11201808106Y A SG 11201808106YA SG 11201808106Y A SG11201808106Y A SG 11201808106YA SG 11201808106Y A SG11201808106Y A SG 11201808106YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lateral sclerosis
- amyotrophic lateral
- masitinib
- pct
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 5
- 239000002139 L01XE22 - Masitinib Substances 0.000 title abstract 3
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004655 masitinib Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 241000928106 Alain Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16162490 | 2016-03-25 | ||
| PCT/EP2017/057134 WO2017162884A1 (en) | 2016-03-25 | 2017-03-24 | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808106YA true SG11201808106YA (en) | 2018-10-30 |
Family
ID=55637258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808106YA SG11201808106YA (en) | 2016-03-25 | 2017-03-24 | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10092564B2 (enExample) |
| EP (1) | EP3240538B1 (enExample) |
| JP (2) | JP7250312B2 (enExample) |
| KR (1) | KR102293847B1 (enExample) |
| CN (1) | CN108883108B (enExample) |
| AU (1) | AU2017236177B2 (enExample) |
| BR (1) | BR112018069515A2 (enExample) |
| CA (1) | CA3018635C (enExample) |
| DK (1) | DK3240538T3 (enExample) |
| EA (1) | EA038531B1 (enExample) |
| ES (1) | ES2899929T3 (enExample) |
| HU (1) | HUE057398T2 (enExample) |
| IL (1) | IL261856B (enExample) |
| MX (1) | MX390495B (enExample) |
| NZ (1) | NZ745778A (enExample) |
| PL (1) | PL3240538T3 (enExample) |
| PT (1) | PT3240538T (enExample) |
| SG (1) | SG11201808106YA (enExample) |
| SI (1) | SI3240538T1 (enExample) |
| WO (1) | WO2017162884A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| JP6499077B2 (ja) | 2012-10-25 | 2019-04-10 | ザ ジェネラル ホスピタル コーポレイション | アルツハイマー病と関連疾患の治療のための併用療法 |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| CA2928028A1 (en) | 2013-10-22 | 2015-04-30 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| CN116889562A (zh) * | 2016-08-31 | 2023-10-17 | 通用医疗公司 | 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞 |
| CN109073634B (zh) | 2016-11-25 | 2022-07-08 | 基诺富公司 | 用于诱导神经干细胞的分化和保护的组合物及使用该组合物诱导神经再生的方法 |
| CN110475555A (zh) * | 2017-03-28 | 2019-11-19 | 诺华股份有限公司 | 治疗多发性硬化的新方法 |
| MX2019014343A (es) * | 2017-05-30 | 2020-08-03 | Deciphera Pharmaceuticals Inc | Uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-n aftiridin-3-il]-2-fluorofenil]-3-fenilurea y analogos para el tratamiento de canceres asociados con anomalias geneticas en el receptor alfa del factor de crecimiento derivado de plaquetas. |
| EP3762013A4 (en) * | 2018-03-05 | 2022-05-11 | The Schepens Eye Research Institute, Inc. | THERAPY FOR GLAUCOMA AND OPTICAL NEUROPATHY BY TARGETING COLONY-STIMULATING FACTORS |
| EP3817739A4 (en) | 2018-07-02 | 2022-04-13 | The General Hospital Corporation | POWDERED FORMULATIONS OF CROMOLYN SODIUM AND ALPHA-LACTOSE |
| KR20210113610A (ko) | 2018-12-10 | 2021-09-16 | 더 제너럴 하스피탈 코포레이션 | 크로몰린 에스테르 및 이의 용도 |
| CN112618717A (zh) * | 2019-09-24 | 2021-04-09 | 北京大学深圳研究生院 | Btk抑制剂用于治疗肌萎缩侧索硬化症的用途 |
| SMT202400484T1 (it) * | 2019-12-30 | 2025-01-14 | Deciphera Pharmaceuticals Llc | Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea |
| US12458622B2 (en) | 2020-04-06 | 2025-11-04 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| WO2025113494A1 (zh) * | 2023-11-27 | 2025-06-05 | 浙江径科医药有限公司 | 多环类化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| MXPA05001277A (es) | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| SI2118099T1 (sl) | 2007-02-13 | 2011-11-30 | Ab Science | Postopek za sintezo 2-aminotiazolnih spojin kot kinaznih inhibitorjev |
| TW201204360A (en) | 2010-04-20 | 2012-02-01 | Ab Science | Treatment of multiple sclerosis with MASITINIB |
| US10272082B2 (en) | 2011-07-13 | 2019-04-30 | Cytokinetics, Inc. | Combination ALS therapy |
| AU2013326463B2 (en) * | 2012-10-04 | 2018-01-18 | Ab Science | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
| JP6553589B2 (ja) * | 2013-03-15 | 2019-07-31 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ピリミド−ジアゼピノン化合物および障害の治療方法 |
| US20160263110A1 (en) * | 2013-11-04 | 2016-09-15 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
-
2017
- 2017-03-24 NZ NZ745778A patent/NZ745778A/en not_active IP Right Cessation
- 2017-03-24 PL PL17712175T patent/PL3240538T3/pl unknown
- 2017-03-24 WO PCT/EP2017/057134 patent/WO2017162884A1/en not_active Ceased
- 2017-03-24 JP JP2018549902A patent/JP7250312B2/ja active Active
- 2017-03-24 CA CA3018635A patent/CA3018635C/en active Active
- 2017-03-24 US US15/545,800 patent/US10092564B2/en active Active
- 2017-03-24 PT PT177121753T patent/PT3240538T/pt unknown
- 2017-03-24 KR KR1020187026871A patent/KR102293847B1/ko active Active
- 2017-03-24 CN CN201780019760.9A patent/CN108883108B/zh active Active
- 2017-03-24 SI SI201730997T patent/SI3240538T1/sl unknown
- 2017-03-24 ES ES17712175T patent/ES2899929T3/es active Active
- 2017-03-24 HU HUE17712175A patent/HUE057398T2/hu unknown
- 2017-03-24 AU AU2017236177A patent/AU2017236177B2/en active Active
- 2017-03-24 SG SG11201808106YA patent/SG11201808106YA/en unknown
- 2017-03-24 DK DK17712175.3T patent/DK3240538T3/da active
- 2017-03-24 MX MX2018011349A patent/MX390495B/es unknown
- 2017-03-24 EP EP17712175.3A patent/EP3240538B1/en active Active
- 2017-03-24 BR BR112018069515A patent/BR112018069515A2/pt not_active Application Discontinuation
- 2017-03-24 EA EA201800499A patent/EA038531B1/ru unknown
-
2018
- 2018-09-20 IL IL261856A patent/IL261856B/en unknown
-
2021
- 2021-12-16 JP JP2021204244A patent/JP2022037132A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180125966A (ko) | 2018-11-26 |
| ES2899929T3 (es) | 2022-03-15 |
| CN108883108B (zh) | 2021-08-06 |
| DK3240538T3 (da) | 2021-12-06 |
| NZ745778A (en) | 2022-07-01 |
| KR102293847B1 (ko) | 2021-08-26 |
| IL261856A (en) | 2018-10-31 |
| EA201800499A1 (ru) | 2019-03-29 |
| PL3240538T3 (pl) | 2022-01-31 |
| MX2018011349A (es) | 2019-02-07 |
| US10092564B2 (en) | 2018-10-09 |
| US20180117037A1 (en) | 2018-05-03 |
| MX390495B (es) | 2025-03-20 |
| SI3240538T1 (sl) | 2022-02-28 |
| JP2022037132A (ja) | 2022-03-08 |
| AU2017236177B2 (en) | 2022-03-31 |
| IL261856B (en) | 2022-04-01 |
| EP3240538A1 (en) | 2017-11-08 |
| EP3240538B1 (en) | 2021-09-29 |
| CA3018635C (en) | 2023-09-26 |
| PT3240538T (pt) | 2021-12-07 |
| BR112018069515A2 (pt) | 2019-04-16 |
| AU2017236177A1 (en) | 2018-09-20 |
| JP7250312B2 (ja) | 2023-04-03 |
| WO2017162884A1 (en) | 2017-09-28 |
| HUE057398T2 (hu) | 2022-05-28 |
| EA038531B1 (ru) | 2021-09-10 |
| CA3018635A1 (en) | 2017-09-28 |
| CN108883108A (zh) | 2018-11-23 |
| JP2019515884A (ja) | 2019-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201808540SA (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
| SG11201901762WA (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| SG11201806157WA (en) | Method and pharmaceutical composition for treatment of neurodegeneration |